NAD+ Precursors and Antioxidants for the Treatment of Amyotrophic Lateral Sclerosis
2021; Multidisciplinary Digital Publishing Institute; Volume: 9; Issue: 8 Linguagem: Inglês
10.3390/biomedicines9081000
ISSN2227-9059
AutoresElena Obrador, Rosario Salvador‐Palmer, Rafael López-Blanch, Ryan W. Dellinger, José M. Estrela,
Tópico(s)Biochemical Acid Research Studies
ResumoCharcot first described amyotrophic lateral sclerosis (ALS) between 1865 and 1874 as a sporadic adult disease resulting from the idiopathic progressive degeneration of the motor neuronal system, resulting in rapid, progressive, and generalized muscle weakness and atrophy. There is no cure for ALS and no proven therapy to prevent it or reverse its course. There are two drugs specifically approved for the treatment of ALS, riluzol and edaravone, and many others have already been tested or are following clinical trials. However, at the present moment, we still cannot glimpse a true breakthrough in the treatment of this devastating disease. Nevertheless, our understanding of the pathophysiology of ALS is constantly growing. Based on this background, we know that oxidative stress, alterations in the NAD
Referência(s)